Holen Sie sich die Stockscreener-App
26.59
3.79%
0.97
Schlusskurs vom Vortag:
$25.62
Offen:
$25.86
24-Stunden-Volumen:
620.07K
Relative Volume:
0.48
Marktkapitalisierung:
$2.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-20.93
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
+4.52%
1M Leistung:
-8.47%
6M Leistung:
-25.66%
1J Leistung:
-18.39%
1-Tages-Spanne:
$25.47
$26.95
1-Wochen-Bereich:
$24.79
$26.95
52-Wochen-Spanne:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.59 | 1.95B | 0 | -64.16M | -69.06M | -1.2702 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment - TipRanks
CG Oncology, Inc. (NASDAQ:CGON) Position Reduced by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Lowers Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology’s SWOT analysis: bladder cancer treatment stock shows promise amid competition - Investing.com
Bank of America Corp DE Has $6.01 Million Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Millennium Management LLC Invests $7.14 Million in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,026 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success - MSN
Deutsche Bank AG Acquires 13,589 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Given New $52.00 Price Target at Morgan Stanley - Defense World
CGON Stock Rating Maintained by Morgan Stanley Despite Price Target Cut | CGON Stock News - GuruFocus
Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by Northern Trust Corp - Defense World
Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Leading Bladder Cancer Drug Developer CG Oncology Takes Stage at Major RBC Healthcare Conference - Stock Titan
CG Oncology (NASDAQ:CGON) Shares Gap Down on Disappointing Earnings - Defense World
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology reports Q1 EPS (45c), consensus (37c) - TipRanks
CGON Q1 Revenue Falls Short; Advances in Bladder Cancer Therapy - GuruFocus
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CG Oncology Q1 Loss Widens, Revenue Falls - marketscreener.com
CG Oncology, Inc. SEC 10-Q Report - TradingView
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Target | CGON Stock News - GuruFocus
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
6.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):